Home

Harlan Waksal

CIK 1449008 · Executive Chair · last filed 2026-07-29

Harlan Waksal is an Executive Chair who has filed 53 SEC Form 4 insider transactions across 4 companies since 2009. The most recent filing, for FRNM, was dated Jul 29, 2026. Across all open-market trades the lifetime net is +$1.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$4.63M

Companies

4

Total Filings

53

Lifetime Open-Market Net

$1.48M

Filer Profile

Reported Address
WAKSAL CONSULTING LLC
7 NORTH WILLOW STREET, SUITE 6
MONTCLAIR, NJ 07042
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FRNM 30,000 — — $0 1 2026-07-29
Lyra Therapeutics, Inc. (LYRA) Delisted Executive Chair 10,739 $0.70 $7.5K $1.07M 7 2024-12-11
Kadmon Holdings, Inc. (KDMN) Delisted President, CEO 0 $9.50 $0 $143.0K 18 2021-11-09
SNT Director 2,805,750 $1.65 $4.63M $263.5K 18 2012-11-16

Recent Filings

53 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-29 FRNM Conv (C) +30,000 $0 EDGAR
2025-04-25 — Notice (144) −145,370 -$14.9K EDGAR
2024-12-11 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2024-03-20 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) +275,000 $0 EDGAR
2023-11-13 Lyra Therapeutics, Inc. (LYRA) Delisted Buy (P) +25,000 $74.1K EDGAR
2023-02-02 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-06-21 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-04-13 Lyra Therapeutics, Inc. (LYRA) Delisted Buy (P) +236,966 $1000.0K EDGAR
2022-02-18 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2021-11-09 Kadmon Holdings, Inc. (KDMN) Delisted Disp (D) −177,945 -$1.69M EDGAR
Showing 1–10 of 53
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.